1-3 of 3
Stuart Bailey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy

Lei Nie, Eric H. Rubin, Nitin Mehrotra, José Pinheiro, Laura L. Fernandes, Amit Roy, Stuart Bailey, Dinesh P. de Alwis
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2623–2629.
https://doi.org/10.1158/1078-0432.CCR-15-2644
Published: 31 May 2016
View article titled, Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy
Open the PDF for Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy in another window
Journal Articles

Advancing Clinical Trials to Streamline Drug Development

Susan E. Bates, Donald A. Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M. LoRusso, Eric H. Rubin
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4527–4535.
https://doi.org/10.1158/1078-0432.CCR-15-0039
Published: 14 October 2015
View article titled, Advancing Clinical Trials to Streamline Drug Development
Open the PDF for Advancing Clinical Trials to Streamline Drug Development in another window
Journal Articles

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez-Ibarra, Hong Lu, Stuart Bailey, Sandra Chica, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3671–3680.
https://doi.org/10.1158/1078-0432.CCR-12-3404
Published: 30 June 2013
View article titled, First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data